The impact of Novo Nordisk A/S’s new diabetes drug is having a broad impact on equity markets. Late Tuesday, Norvo Nordisk A/s, Europe’s largest company by market value, said it was halting a study that looked at the impact of its diabetes drug Ozempic drug on kidney failure after it showed effectiveness surprisingly early. The news sent global kidney dialysis providers tumbling today, just one sector to feel the effects of the new diabetes drug.
Novo Nordisk A/S’s Ozempic and Wegovy injectable drugs are a class of weight-loss medicines known as GLP-1s. The impact of these drugs has expanded beyond obesity and diabetes. Another recent study showed Wegovy cut the risk of heart attacks and strokes. Citigroup said, “The body of evidence to support GLP-1 use, over and above weight loss and blood glucose control, continues to grow.” These GLP-1 drugs have caused wide effects across the stock market for the makers of everything from snacks to liquor.
